Premium
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib
Author(s) -
Adachi Takuya,
Nouso Kazuhiro,
Miyahara Koji,
Oyama Atsushi,
Wada Nozomu,
Dohi Chihiro,
Takeuchi Yasuto,
Yasunaka Tetsuya,
Onishi Hideki,
Ikeda Fusao,
Nakamura Shinichiro,
Shiraha Hidenori,
Takaki Akinobu,
Takabatake Hiroyuki,
Fujioka Shinichi,
Kobashi Haruhiko,
Takuma Yoshitaka,
Iwadou Shouta,
Uematsu Shuji,
Takaguchi Koichi,
Hagihara Hiroaki,
Okada Hiroyuki
Publication year - 2019
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.14535
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , hazard ratio , oncology , angiopoietin 2 , angiogenesis , univariate analysis , proportional hazards model , vascular endothelial growth factor , gastroenterology , confidence interval , multivariate analysis , vegf receptors
Background and Aim Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one‐time measurements before treatment. Methods We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results Among six significant risk factors for overall survival in univariate analyses, high angiopoietin‐2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin‐2 at the time of progressive disease was a marker of short post‐progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression‐free survival except the presence of hepatitis B virus surface antigen. Conclusions Predictions of overall survival and post‐progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin‐2, in patients with HCC treated with sorafenib.